Fairmount Funds Management LLC 13F: Quarter-over-Quarter Portfolio Changes
Fairmount Funds Management LLC reported a disclosed portfolio value of approximately $1.4 billion in its latest SEC Form 13F-HR filing for Q1 2026, up 5.4% quarter on quarter. Over the quarter, the fund initiated 1 new position, bought more shares in 2 holdings, trimmed 3 holdings, and exited 2 positions.
Fairmount Funds Management LLC's top buy was a new stake in Damora Therapeutics INC (DMRA) , equal to 16.3% of the disclosed portfolio. Its top sell was Apogee Therapeutics INC (APGE) . The fund sold 85.4% of its previously reported shares, reducing the position's portfolio weight by 10.0 percentage points.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| DAMORA THERAPEUTICS INC | DMRA | 16.3% | History → |
Top BuysQ1 2026
The fund's top buys among existing positions in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| DIANTHUS THERAPEUTICS IN | DNTH | +8.7% | +18.7% | History → |
| ZENAS BIOPHARMA INC | ZBIO | +-2.8% | +6.8% | History → |
Top SellsQ1 2026
The fund's top sells among positions it retained in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| APOGEE THERAPEUTICS INC | APGE | -10.0% | 85.4% | Holders → |
| ENLIVEN THERAPEUTICS INC | ELVN | 0.9% | 50.0% | History → |
| COGENT BIOSCIENCES INC | COGT | -9.0% | 38.9% | History → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| NUVALENT INC | NUVL | 5.6% |
| KINIKSA PHARMACEUTICALS I | KNSA | 4.1% |
Net Portfolio Value ChangeQ1 2026
- $1.3BPrior quarter
- $1.4BCurrent quarter
- +$0.1BNet delta
- +5.4%% change
Methodology & FAQ
How Fairmount Funds Management LLC Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Fairmount Funds Management LLC: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Fairmount Funds Management LLC buy in Q1 2026?
In Q1 2026, Fairmount Funds Management LLC initiated 1 new position (DAMORA THERAPEUTICS INC (DMRA)); bought more shares of DIANTHUS THERAPEUTICS IN (DNTH), ZENAS BIOPHARMA INC (ZBIO).
What stocks did Fairmount Funds Management LLC sell in Q1 2026?
In Q1 2026, Fairmount Funds Management LLC fully sold 2 positions (NUVALENT INC (NUVL), KINIKSA PHARMACEUTICALS I (KNSA)); reduced holdings in APOGEE THERAPEUTICS INC (APGE), ENLIVEN THERAPEUTICS INC (ELVN), COGENT BIOSCIENCES INC (COGT).
Which positions did Fairmount Funds Management LLC initiate in Q1 2026?
Fairmount Funds Management LLC established 1 new position in Q1 2026: DAMORA THERAPEUTICS INC (DMRA, 16.3%).
Which existing positions saw the largest allocation increases for Fairmount Funds Management LLC in Q1 2026?
Of 2 existing positions with share-count increases in Q1 2026, the largest were: DIANTHUS THERAPEUTICS IN (DNTH, +8.7% weight, +18.7% shares), ZENAS BIOPHARMA INC (ZBIO, +-2.8% weight, +6.8% shares).
Which positions did Fairmount Funds Management LLC fully exit in Q1 2026?
Fairmount Funds Management LLC fully exited 2 positions in Q1 2026: NUVALENT INC (NUVL, last-reported weight 5.6%), KINIKSA PHARMACEUTICALS I (KNSA, last-reported weight 4.1%).
Which existing positions saw the largest allocation reductions for Fairmount Funds Management LLC in Q1 2026?
Of 3 existing positions with share-count reductions in Q1 2026, the largest were: APOGEE THERAPEUTICS INC (APGE, -10.0% weight, -85.4% shares), ENLIVEN THERAPEUTICS INC (ELVN, 0.9% weight, -50.0% shares), COGENT BIOSCIENCES INC (COGT, -9.0% weight, -38.9% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.